Insider Selling: Twist Bioscience Corporation (NASDAQ:TWST) CEO Sells 1,678 Shares of Stock

Twist Bioscience Corporation (NASDAQ:TWST - Get Free Report) CEO Emily M. Leproust sold 1,678 shares of Twist Bioscience stock in a transaction on Friday, June 20th. The shares were sold at an average price of $35.76, for a total transaction of $60,005.28. Following the completion of the sale, the chief executive officer now owns 645,782 shares in the company, valued at approximately $23,093,164.32. This represents a 0.26% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website.

Twist Bioscience Stock Down 2.7%

Shares of NASDAQ:TWST opened at $35.93 on Friday. The company has a quick ratio of 4.24, a current ratio of 4.51 and a debt-to-equity ratio of 0.03. The business's 50 day moving average is $33.53 and its 200 day moving average is $40.59. The stock has a market cap of $2.15 billion, a P/E ratio of -11.06 and a beta of 2.38. Twist Bioscience Corporation has a 52-week low of $27.12 and a 52-week high of $60.90.

Twist Bioscience (NASDAQ:TWST - Get Free Report) last released its quarterly earnings data on Monday, May 5th. The company reported ($0.66) earnings per share for the quarter, missing analysts' consensus estimates of ($0.56) by ($0.10). Twist Bioscience had a negative return on equity of 33.48% and a negative net margin of 54.98%. The business had revenue of $92.79 million during the quarter, compared to analysts' expectations of $92.00 million. Sell-side analysts predict that Twist Bioscience Corporation will post -2.12 EPS for the current year.

Institutional Trading of Twist Bioscience

Hedge funds and other institutional investors have recently bought and sold shares of the stock. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its stake in Twist Bioscience by 186.1% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 2,442,262 shares of the company's stock valued at $95,883,000 after purchasing an additional 1,588,587 shares during the last quarter. First Light Asset Management LLC purchased a new position in Twist Bioscience in the fourth quarter worth $56,984,000. EdgePoint Investment Group Inc. acquired a new position in shares of Twist Bioscience during the first quarter worth $43,705,000. Marshall Wace LLP grew its stake in Twist Bioscience by 15,927.8% during the 4th quarter. Marshall Wace LLP now owns 846,107 shares of the company's stock worth $39,319,000 after buying an additional 840,828 shares during the last quarter. Finally, Nuveen LLC acquired a new position in Twist Bioscience during the 1st quarter valued at about $31,960,000.

Analyst Ratings Changes

Several brokerages have recently issued reports on TWST. Guggenheim restated a "buy" rating and set a $50.00 target price on shares of Twist Bioscience in a research report on Tuesday, May 6th. Robert W. Baird cut their target price on Twist Bioscience from $54.00 to $44.00 and set an "outperform" rating on the stock in a research report on Tuesday, May 6th. JPMorgan Chase & Co. lowered their price target on Twist Bioscience from $40.00 to $33.00 and set an "underweight" rating for the company in a research report on Tuesday, May 6th. Barclays dropped their price objective on shares of Twist Bioscience from $58.00 to $45.00 and set an "overweight" rating for the company in a research note on Thursday, April 10th. Finally, The Goldman Sachs Group reduced their target price on shares of Twist Bioscience from $55.00 to $48.00 and set a "buy" rating on the stock in a research note on Tuesday, May 6th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and eight have issued a buy rating to the company. According to data from MarketBeat.com, Twist Bioscience currently has an average rating of "Moderate Buy" and a consensus target price of $50.40.

Twist Bioscience Company Profile

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.